We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Celgene today announced that it has completed the acquisition of Juno Therapeutics, Inc. As a result, the common stock of Juno will no longer be listed for trading on the NASDAQ Global Select Market